Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparative effectiveness of telitacicept versus belimumab in systemic lupus erythematosus
ChiCTR2500110784Phase 4Not yet recruiting
- Sponsor
- Shandong Provincial Qianfoshan Hospital
- Start
- Oct 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of telitacicept and belimumab in systemic lupus erythematosus (SLE) (2 cohorts), sponsored by Shandong Provincial Qianfoshan Hospital. Primary endpoint: Response rate of systemic lupus erythematosus. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
telitaciceptbelimumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on ChiCTR2500110784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500110784.